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Since it was first performed by Go et al. in 1992 and first reported by Higashihara et al. in Japan (1, 2) , laparoscopic adrenalectomy has rapidly become the preferred approach and gold standard for the surgical treatment of benign adrenal tumors. Compared with open adrenalectomy, laparoscopic adrenalectomy using three or four ports is associated with decreased morbidity, shorter hospital stay, decreased postoperative pain, rapid convalescence, and superior cosmesis, but it still has some limitations (3, 4) . Because conventional laparoscopic adrenalectomy (CLA) requires several incisions for multiple trocars, each measuring at least 0.5-2.0 cm in length, it carries a potential risk of morbidity involving port-site complications, such as bleeding, pain, infection, and hernia, and might pose some aesthetic disadvantages. Following the advancements in laparoscopic instrumentation, laparoendoscopic single-site (LESS) surgery has been introduced as a novel urologic surgical procedure for minimizing postoperative pain and improving cosmetic outcomes. LESS surgery is a single-port or single-incision laparoscopic procedure, which makes it suitable for adrenalectomy as it requires no incision lengthening for specimen extraction. In 2005, Hirano et al. first reported 54 cases of retroperitoneoscopic adrenalectomy using a single port inserted through an incision below the 12th rib (5) . Subsequently, many studies provided evidence that LESS adrenalectomy (LESS-A) is a safe and feasible alternative to CLA (6, 7) . To further improve cosmesis, embryonic natural natural orifice translumenal endoscopic surgery (E-NOTES) via the vagina, mouth/stomach, rectum, and umbilicus has recently been developed as a novel scarless surgical technique (8, 9) . In 2008, Castellucci et al. reported the first experience of a supraumbilical single-port adrenalectomy (10) , and in 2012, Miyajima et al. reported the first transumbilical LESS-A (11).
Indeed, the transumbilical approach appears to be less invasive and confer better cosmetic advantage than other approaches. However, postoperative pain and cosmesis after transumbilical LESS-A have been based mainly on surgeons' subjective evaluations. Therefore, to objectively evaluate patients' postoperative pain, body image, and cosmetic satisfaction after transumbilical LESS-A, we assessed patient-reported outcomes using a conventional method for patient reporting of pain and scarring.
Materials and Methods

Patients
The protocol for the present study was approved by the institutional review board of Oita University and conducted in accordance with the principles of the Declaration of Helsinki.
We studied 24 consecutive patients with benign adrenal tumors (12 primary aldosteronism, 6 Cushing's syndrome, 1 pheochromocytoma, and 5 other tumors) who underwent transumbilical LESS-A between July 2009 and September 2016. Before the operation, verbal and written informed consent was obtained from all patients.
A visual analog scale (VAS) was used for the objective assessment of postoperative incisional pain for 7 consecutive days. The VAS score of postoperative pain was determined by the attending nurse twice daily using a 10-point Likert scale ranging from 0 (no pain) to 10 (excruciating pain). The highest pain score was used for analysis. To assess body image and cosmetic satisfaction, a body image questionnaire created by Dunker et al. was used (12) . The body image questionnaire has eight items comprising a body image scale (BIS) and a cosmetic scale (CS), each with high international acceptance. The BIS measures a patient's perception of and satisfaction with the aesthetics or sexual attractiveness of their own body after surgery. The BIS score range is from 5 to 20 points, and a higher score represents a high degree of body image satisfaction. The CS assesses explicit satisfaction with a scar's physical appearance. The total CS range is from 3 to 24 points, and a higher score represents greater cosmetic satisfaction. Patients were asked to complete the body image questionnaire on the day of the clinic visit or by mail within 1 month and more than 3 months after surgery.
Surgical technique
The procedures were performed by three technically skilled surgeons (HM, FS, and TN). The patient was placed in the semilateral position. A 1.5-3.5-cm periumbilical longitudinal skin incision was made at the inner edge of the umbilicus for port placement; the incision length varied depending on the tumor size. The anterior rectus fascia was sharply incised as much as possible to permit comfortable movement of the instruments. Subsequently, a multichannel port (GelPOINT Mini; Applied Medical Resources, Rancho Santa Margarita, USA) was placed into the peritoneum through the incision. The GelPOINT was also used for a case of large adrenal myelolipoma. Three 5-mm trocars were placed through the access platform. In case of reduced-port surgery, an additional 3-mm trocar was used in right-sided adrenal tumors for liver retraction. To avoid instrument collision, a flexible 5-mm laparoscope (Olympus, Tokyo, Japan) was used. Standard laparoscopic instruments were mainly used for dissection, and articulating instruments were used as required to achieve triangulation.
The white line of Toldt was incised, and the plane of Gerota's fascia was dissected until the vascular landmarks (inferior vena cava and renal vein for right-and left-sided adrenal tumors, respectively) were revealed. After the adrenal vein was divided using a LigaSure Blunt Tip 44-cm sealer and divider (Covidien, Mansfield, USA), the adrenal gland containing the tumor was completely released from the upper pole of the kidney. The specimen was placed in an Endobag (Endo-Catch Gold ™ ; Covidien) and retrieved with the GelPOINT Mini to minimize spillage and contamination by isolating and containing specimen. The specimens were extracted without any additional extension of the umbilical incision, with the exception of an 89 × 75 × 60-mm adrenal myelolipoma in the left adrenal gland. After a pneumoperitoneum was reestablished to carefully inspect for bleeding, a suction drainage tube was left in place through the single skin incision. The umbilical rectus fascia was closed with an interrupted 2-0 absorbable suture, and the skin was closed with a 4-0 buried absorbable suture.
Statistical analysis
All statistical analyses were performed using the Statcel3 software (OMS Publishing Inc., Tokyo, Japan). Data were expressed as means ± SD. Spearman's rank correlation analysis was used to assess the learning curve on operative time and pneumoperitoneum time. A paired t-test was performed to evaluate the differences in VAS scores. A value of P < 0.05 was considered statistically significant. Tables 1 and 2 . The mean tumor size was 23.8 ± 17.3 mm (range, 9.0-89.0 mm), and a case of adrenal myelolipoma measuring 89 × 75 × 60 mm required a 1.5-cm extension of the umbilical incision to remove the specimen. The mean estimated blood loss was 41.4 ± 101.5 mL, but one patient with liver injury had a blood loss of 500 mL. Liver laceration occurred in one patient who had reduced-port adrenalectomy for a right adrenal tumor; it occurred when the liver was raised with an ENDOPATH 5-mm Blunt Cherry Dissector (Ethicon, New Brunswick, USA) with excessive traction. Hemostasis was obtained with electrical coagulation and the placement of a fibrinogen/thrombin-coated collagen patch (TachoSil; CSL, Victoria, Australia). None of the patients required blood transfusion, and the postoperative course during the 3-month follow-up was uneventful with no morbidity. The operative time did not correlate with the number of cases (y = 0.1443x + 201.53, r = 0.017554) (Figure 1a) , and similarly, the pneumoperitoneum time did not correlate with the number of cases (y = 0.6065x + 137.29, r = 0.0987501) (Figure 1b) . The mean duration of analgesic treatment to manage postoperative pain was 2 days (range, 0-7 days). All patients started oral intake and ambulation on the first postoperative day. None of the patients required postoperative narcotics, and only analgesics and nonsteroidal anti-inflammatory drugs (loxoprofen sodium 60 mg and/or diclofenac sodium suppository 50 mg) were available on demand. The mean VAS score for incisional pain on postoperative days 1, 3, and 7 was 3.5 ± 1.6, 2.2 ± 1.3, and 1.5 ± 1.0 points, respectively (Figure 2a) . A significant decrease in VAS scores occurred on postoperative day 3 (P = 0.012), and a time-dependent reduction in postoperative pain was observed.
Results
Transumbilical LESS-
The assessment of cosmesis showed that the skin incision was almost concealed within the umbilicus for all patients, Values are presented as mean ± SD and the umbilical scar was invisible (Figure 2b) . Of the 24 patients, 16 patients (66.7%) (8 retrospective, 8 prospective) completed the cosmesis survey; 8 patients were lost to clinical follow-up and excluded from this section of the present study. According to the patients' self-assessments, the mean BIS and CS scores at 1 month after surgery were 20 ± 0.4 and 22 ± 2.6 points, respectively (Figure 2c,d) . Similarly, the mean BIS and CS scores at 3 months after surgery were 19 ± 2.2 and 21 ± 4.7 points, respectively (Figure 2c,d) . These results demonstrated a timedependent decrease in the BIS and CS scores, and no significant differences were observed between the groups. During the study period, there were no significant differences between the pure-LESS group and the additional ports group with regard to VAS scores for incisional pain and BIS and CS scores.
Discussion
For LESS-A, a transperitoneal approach via a pararectal incision or a retroperitoneal approach via an incision below the tip of the 12th rib greatly facilitates access to the adrenal gland and vascular landmarks (5, 13) . Although these approaches make LESS-A a safe and feasible method, a clear surgical scar remains. To minimize invasiveness and improve cosmesis, a new strategy called embryonic NOTES has been introduced; it is the cutting edge of surgical innovation for scarless surgery (8, 9) . Few publications have objectively evaluated postoperative pain, cosmetic outcomes, Pain and cosmesis in LESS adrenalectomy T Nomura et al.
and patients' scar satisfaction after LESS-A. In general, the evaluation of postoperative pain and aesthetic outcomes is considered difficult because of the absence of a reliable objective method for doing so. In the present study, we objectively assessed the tolerance of postoperative pain and cosmesis using a conventional method for patient reporting of pain and scarring outcomes. For invasiveness, we evaluated the operative time, blood loss, intraoperative complications, and postoperative hospitalization. These factors did not differ significantly between patients who underwent CLA and those who underwent transumbilical LESS-A (data not shown). Ishida et al. reported that the clinical outcomes of transumbilical LESS-A were comparable to those of CLA, but LESS-A patients had a significantly shorter postoperative hospital stay (14) . One of the prime benefits of laparoscopic surgery is reduced postoperative pain. Although we have no data on postoperative pain after CLA, patients who underwent transumbilical LESS-A had lower pain scores and required less analgesia than those who underwent CLA. In the present study, the level of postoperative pain differed on an individual basis. Nevertheless, postoperative pain was quickly relieved, and healing occurred within 2-4 weeks after surgery (data not shown). A matched case-control study reported that patients who underwent LESS-A had significantly lower postoperative pain and significantly shorter duration of postoperative analgesic usage than those who underwent CLA (6). Sasaki et al. also demonstrated that patients who had undergone transumbilical LESS-A had lower VAS scores of incisional pain and lower frequency of analgesic consumption than those who had undergone CLA (15) . Based on our results and those of previous reports, it appears reasonable to suggest that transumbilical LESS-A is potentially associated with reduced postoperative pain and operative outcomes that are equivalent to those of CLA.
Patients' body image and cosmetic satisfaction were reflected in high BIS and CS scores at postoperative follow-up. The umbilical scar was only barely visible, and the scar from the 3-mm trocar was almost invisible. Patients had excellent cosmesis and high cosmetic satisfaction. However, it was unclear whether the level of patient satisfaction with body image and cosmetic outcomes after transumbilical LESS-A were higher than those after CLA. Scar satisfaction has been reported to be comparable between CLA and transumbilical LESS-A (16). However, LESS-A patients may have even greater scar satisfaction if they were to compare their outcomes to those of CLA patients. In other words, cosmetic satisfaction may be influenced by both the port insertion sites and by the number of port scars. In fact, Wang et al. reported that after the patients viewed photographs of alternative scars, the cosmesis ratings of patients who underwent transumbilical LESS-A statistically improved relative to those who underwent transperitoneal or retroperitoneal subcostal LESS-A. This was true even if the self-scar cosmesis ratings were similar between the different approaches before the patients viewed the photographs (17) . Because transumbilical LESS-A leaves no visible scar, higher patient satisfaction with the aesthetic outcomes should be anticipated.
In general, men and older adults may assign much less importance to body dissatisfaction than women and younger people (18) . The cosmetic value of transumbilical LESS-A, or any scarless surgery, may be acceptable and desirable particularly in young and female patients. In the present study, the cosmetic outcomes were most gratifying, for patients although variations in patients' expectations created assessment challenges. A further prospective study comparing the cosmetic outcomes of transumbilical LESS-A and CLA is required to evaluate the cosmetic advantage conferred by transumbilical LESS-A.
Only after safety has been maintained and complications minimized can the additional aspects of pain reduction and excellent cosmesis be considered. The difficulty of performing transumbilical LESS-A depends on the angle of approach to the target organ and the challenges of handling and retracting organs. We were able to perform transumbilical LESS-A using a flexible 5-mm laparoscope and articulating instruments, which were beneficial for providing triangulation with reduced instrument collision. In LESS surgery, instruments get caught in "sword fights," and the operator's hand can easily come in contact with scopist's hand. Both can lead to significant discomfort and difficulties in LESS surgery, which may act as a barrier to its spread as a standard approach. To reduce "sword fighting," mastery of the "cross-over technique" and the use of articulating instruments are important. We also used an EndoGrab ™ to retract organs and to ensure adequate exposure of the operation area. Better coordination between the operator and the scopist enables comfortable maneuverability. While the indication for LESS-A in obese patients remains controversial, we believe that the surgical indication in obese patients is the same as in non-obese patients. However, in obese patients, we inserted additional 3-mm trocars or converted to reduced-port surgery because an abdominal scar from a 3-mm trocar is only barely visible. Because it is difficult to maintain an adequate operative view in obese patients, the operative time tends to be prolonged, and the surgical stress may increase. Although we could perform pure LESS-A in a patient with a BMI of 32.3 kg/m 2 , we placed additional trocars in case the target organ and/or the vascular landmark could not be identified within 120 min and the surgery could not proceed as scheduled. Regardless, it should be emphasized that whenever there is a risk of injuring the patient during operation, additional trocars should be inserted or the procedure should be converted to reduced-port surgery and/or standard CLA without hesitation. To spread LESS-A more widely as a standard approach, it is essential to develop surgical instruments, such as a tiny, high-resolution, flexible laparoscope, and to master advanced techniques. Additionally, reducedport laparoscopic adrenalectomy using needlescopic instruments (needlescopic-assisted LESS-A) may be considered because it reduces the limitations of pure LESS-A. In general, LESS surgery could be adapted for diseases in which the organs to be excised are small, such as benign adrenal tumors and urachal remnant diseases in urologic surgeries. In particular, LESS surgery is good options for patients, particularly young and female patients, who strongly value cosmetic outcomes.
In conclusion, transumbilical LESS-A appears to be a safe and technically feasible procedure for an experienced surgeon. It offers the potential of reduced postoperative pain and improved cosmetic outcomes. Therefore, this procedure is an excellent promising option for the treatment of benign adrenal tumors.
